{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:43:48Z","timestamp":1792622628366,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82,170,541"],"award-info":[{"award-number":["82,170,541"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.heliyon.2024.e28132","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T12:54:22Z","timestamp":1710334462000},"page":"e28132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Novel insights into post-marketing adverse events associated with lenvatinib: A comprehensive analysis utilizing the FAERS database"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4115-3332","authenticated-orcid":false,"given":"Zhe","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongshan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e28132_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.heliyon.2024.e28132_bib2","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e28132_bib3","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.heliyon.2024.e28132_bib4","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e28132_bib5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e28132_bib6","article-title":"Case report: posterior reversible encephalopathy syndrome, an adverse effect of lenvatinib and pembrolizumab combination therapy, in a patient with advanced endometrial cancer","volume":"12","author":"Matsuura","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e28132_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/17425255.2018.1461839","article-title":"Lenvatinib-induced renal failure: two first-time case reports and review of literature","volume":"14","author":"Cavalieri","year":"2018","journal-title":"Expert Opin Drug Met"},{"key":"10.1016\/j.heliyon.2024.e28132_bib8","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2169\/internalmedicine.7300-21","article-title":"Lenvatinib-induced interstitial pneumonia in a patient with hepatocellular carcinoma","volume":"61","author":"Imakura","year":"2022","journal-title":"Intern Med"},{"key":"10.1016\/j.heliyon.2024.e28132_bib9","first-page":"1","article-title":"A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database","volume":"0","author":"Yang","year":"2023","journal-title":"Expert Opin Drug Met"},{"key":"10.1016\/j.heliyon.2024.e28132_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1169735","article-title":"Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system","volume":"14","author":"Shu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e28132_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.862508","article-title":"Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system","volume":"13","author":"Shu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e28132_bib12","article-title":"Comparing adverse events of tenecteplase and alteplase: a real-world analysis of the FDA adverse event reporting system (FAERS)","author":"Shi","year":"2023","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.heliyon.2024.e28132_bib13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000510369","article-title":"High prevalence and conservative management of acute cholecystitis during lenvatinib for advanced thyroid cancer","volume":"10","author":"Di Stefano","year":"2021","journal-title":"Eur. Thyroid J."},{"key":"10.1016\/j.heliyon.2024.e28132_bib14","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1200\/JCO.20.03093","article-title":"Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer","volume":"39","author":"Wirth","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e28132_bib15","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/bjc.2012.154","article-title":"A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours","volume":"106","author":"Boss","year":"2012","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.heliyon.2024.e28132_bib16","article-title":"Risk factors for hepatic encephalopathy in hepatocellular carcinoma after sorafenib or lenvatinib treatment: a real-world study","volume":"16","author":"B","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.heliyon.2024.e28132_bib17","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e28132_bib18","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1002\/onco.13566","article-title":"FDA supplemental approval summary: lenvatinib for the treatment of unresectable hepatocellular carcinoma","volume":"26","author":"Nair","year":"2021","journal-title":"Oncol."},{"key":"10.1016\/j.heliyon.2024.e28132_bib19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000514182","article-title":"Prevalence and risk factors of developing fistula or organ perforation in patients treated with lenvatinib for radioiodine-refractory thyroid cancer","volume":"10","author":"Valerio","year":"2021","journal-title":"Eur. Thyroid J."},{"key":"10.1016\/j.heliyon.2024.e28132_bib20","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ando.2023.03.009","article-title":"Endocrine-related adverse conditions induced by tyrosine kinase inhibitors","volume":"84","author":"De Leo","year":"2023","journal-title":"Ann. Endocrinol."},{"key":"10.1016\/j.heliyon.2024.e28132_bib21","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.21037\/gs-20-462","article-title":"Bilateral pneumothorax in a patient with anaplastic thyroid carcinoma and lung metastasis during lenvatinib therapy: a case report","volume":"9","author":"Lee","year":"2020","journal-title":"Gland Surg."},{"key":"10.1016\/j.heliyon.2024.e28132_bib22","doi-asserted-by":"crossref","first-page":"963","DOI":"10.21037\/gs-22-71","article-title":"Lung cavitation in patients with anaplastic thyroid cancer treated with lenvatinib","volume":"11","author":"Murayama","year":"2022","journal-title":"Gland Surg."},{"key":"10.1016\/j.heliyon.2024.e28132_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00280-023-04519-6","article-title":"Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma","volume":"91","author":"Legros","year":"2023","journal-title":"Cancer Chemoth Pharm"},{"key":"10.1016\/j.heliyon.2024.e28132_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.2312","article-title":"Disproportionality analysis of lenvatinib-caused gastrointestinal perforation in cancer patients: a pharmacovigilance based on the Food and drug administration adverse event reporting system","author":"Zhou","year":"2023","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e28132_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1160117","article-title":"Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis","volume":"14","author":"Xue","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e28132_bib26","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1177\/1078155218817109","article-title":"Wound healing complications with lenvatinib identified in a pharmacovigilance database","volume":"25","author":"Cheng","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.heliyon.2024.e28132_bib27","article-title":"Psychiatric adverse reactions to non-selective RET multi-kinase inhibitors: a large-scale pharmacovigilance analysis","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Pharmacol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402404163X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402404163X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:39:00Z","timestamp":1782247140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402404163X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S240584402404163X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28132","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel insights into post-marketing adverse events associated with lenvatinib: A comprehensive analysis utilizing the FAERS database","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e28132"}}